The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Zaltzman, Alina S. R
Glick, Lauren A.
Zaltzman, Jeffrey S.
Prasad, G. V. Ramesh
Funding for this research was provided by:
Astellas Pharma US